A Phase II, Open Label, Multi-center Study of EP2101 Therapeutic Vaccine in Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase II
Latest Information Update: 09 Sep 2015
At a glance
- Drugs OSE 2101 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Epimmune
- 09 Sep 2015 Results of subgroup analysis presented at the 16th World Conference on Lung Cancer.
- 02 Jun 2008 Results presented at the Annual Meeting of the American Society of Clinical Oncology 2008, according to an IDM Pharma media release.
- 16 May 2008 Data will be presented at ASCO 2008 according to a IDM Pharma media release.